Clinical Trial Update: Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating consistency and non-inferiority bridging between batches of a recombinant CHO cell-based COVID-19 vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• recombinant New Coronavirus Vaccine (CHO Cells)

Snippet

Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Coronavirus Disease 2019 | Phase 3 | Status: UNKNOWN